ATRIA Bleeding Risk Score
Determines bleeding risk for patients being considered for warfarin anticoagulation
作成者Males: Hemoglobin <13 g/dL
Females: Hemoglobin <12 g/dL
The ATRIA Bleeding Risk Score considers major and minor risk of hemorrhage and bleeding in patients prior to beginning warfarin therapy.
The ATRIA study included patients with non-valvular, non-transient atrial fibrillation.
Major hemorrhage was defined as fatal, requiring transfusion of ≥2 units pRBCs, or hemorrhage into critical anatomic site (intracranial, retroperitoneal, etc.)
Criteria
Risk Factor | Point Value |
Anemia | 3 |
Severe Renal Disease/Dialysis | 3 |
Age ≥75 | 2 |
Prior Hemorrhage | 1 |
Hypertension | 1 |
Results
Risk Level | Points | Annual Risk of Hemorrhage | Recommendation |
Low Risk | <4 | 0.76% | Reasonable to start warfarin therap |
Intermediate Risk | 4 | 2.6% | Alternatives to warfarin therapy can be considered |
High Risk | >4 | 5.8% | Alternatives to warfarin therapy ought to be strongly considered |
すべての質問と考えられる結果
Questionsタイトルは非表示です
Anemia
Males: Hemoglobin <13 g/dL
Females: Hemoglobin <12 g/dL
Select one option:
- No
- Yes
Severe Renal Disease
Glomerular filtration rate <30mL/min or dialysis-dependent
Select one option:
- No
- Yes
Age ≥ 75 years
Select one option:
- No
- Yes
Any Prior Hemorrhage Diagnosis
Example: GI bleed or intracranial hemorrhage
Select one option:
- No
- Yes
Hypertension History
Select one option:
- No
- Yes
考えられる結果
High Risk (>4 points): Alternatives to warfarin therapy ought to be strongly considered
5.8% Annual Risk of Hemorrhage
- Carefully weigh patient specific risks and benefits of long-term warfarin therapy.
- The ATRIA risk score is one of several tools to stratify the risk of major hemorrhage in patients being considered for warfarin anticoagulation. The HAS-BLED score is another tool that may have a better prediction accuracy than ATRIA.
Low Risk (<4 points): Reasonable to start warfarin therapy
0.76% Annual Risk of Hemorrhage
- Carefully weigh patient specific risks and benefits of long-term warfarin therapy.
- The ATRIA risk score is one of several tools to stratify the risk of major hemorrhage in patients being considered for warfarin anticoagulation. The HAS-BLED score is another tool that may have a better prediction accuracy than ATRIA.
Intermediate Risk (4 points): Alternatives to warfarin therapy can be considered
2.6% Annual Risk of Hemorrhage
- Carefully weigh patient specific risks and benefits of long-term warfarin therapy.
- The ATRIA risk score is one of several tools to stratify the risk of major hemorrhage in patients being considered for warfarin anticoagulation. The HAS-BLED score is another tool that may have a better prediction accuracy than ATRIA.
文献
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19;58(4):395-401.
https://www.jacc.org/doi/10.1016/j.jacc.2011.03.031?articleid=1146658Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013 Jan;143(1):179-184.
https://pubmed.ncbi.nlm.nih.gov/22722228/Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med. 2016 Jun;129(6):600-7.
https://pubmed.ncbi.nlm.nih.gov/26482233/
- 作成者
Dr. Daniel Singer, MDProfessor of medicine at Harvard Medical School and professor in the Department of Epidemiology at Harvard School of Public Health and chief of the Clinical Epidemiology Unit in the General Medicine Division at Massachusetts General Hospital (MGH).
- 提供元
EVAL Foundation
- 寄稿者 · 査読者
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation